Corvus Pharmaceuticals, Inc.
NASDAQ:CRVSBiotechnology
-$0.19 today
- Market cap
- $859.56M
- Beta
- 0.84
- P/E (TTM)
- -24.1
- EPS (TTM)
- -$0.49
Volume 0.99M
Average 1.49M
CRVS Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Corvus Pharmaceuticals, Inc.NASDAQ: CRVS
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows in line with its trailing trend
Q1 FY2026 depreciation & amortization of $29K rose 31.8% year over year, behind the +33.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 11.5% from the prior quarter. Over 3 fiscal years it compounded at -34.1% a year.
Context
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +31.8% toward the trailing-twelve-month pace of +33.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 105K USD
- Year-over-year change
- +23.5%
- 4-year CAGR
- -30.9%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 105K | +23.5% |
| FY2024 | 2024-12-31 | 85K | -43.7% |
| FY2023 | 2023-12-31 | 151K | -58.9% |
| FY2022 | 2022-12-31 | 367K | -20.2% |
| FY2021 | 2021-12-31 | 460K | — |
Depreciation & Amortization vs competitors
How CRVS compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +33.3% is the 2nd highest of 8, against a peer median of -21.9%.
- Over three fiscal years its annual growth of -34.1% compares with a peer median of -15.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $10M USD | +0.0% | +18.6% | 8.5% | |
| LTM Mar 2026 | $7.09M USD | -5.1% | -15.4% | 4.5% | |
| FY2025 | €5.09M EUR | +155.3% | -51.8% | 182.7% | |
| LTM Mar 2026 | $3.76M USD | -21.9% | +2.0% | 8.0% | |
| LTM Mar 2026 | $1.24M USD | -26.3% | -17.4% | 3.5% | |
| LTM Mar 2026 | $1.12M USD | -32.0% | -8.2% | — | |
| LTM Jun 2024 | $931.31K USD | — | -25.6% | 114.2% | |
| LTM Jun 2026 | $537K USD | -72.7% | -56.2% | 1.0% | |
| LTM Mar 2026 | $112K USD | +33.3% | -34.1% | — | |
| LTM Mar 2026 | $0 USD | — | -0.5% | 0.0% | |
| Peer median (excluding CRVS) | — | -21.9% | -15.4% | 6.3% | |
Competitors are the stored peer set for CRVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 105K |
| Gross Profit | 0 | 0 | 0 | 0 | (105K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 29.12M | 24.47M | 16.53M | 19.39M | 33.72M |
| Selling, General & Admin | 9.52M | 8.1M | 6.88M | 8.16M | 9.25M |
| Operating Expenses | 38.63M | 32.57M | 23.41M | 27.55M | 42.87M |
| Depreciation & Amortization | 460K | 367K | 151K | 85K | 105K |
| EBITDA | (42.77M) | (40.94M) | (26.88M) | (62.21M) | (15.18M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (38.63M) | (32.57M) | (23.41M) | (27.55M) | (42.97M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 654K | 1.58M | 1.82M | 2.51M |
| Interest Expense | 15K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (4.61M) | (8.74M) | (3.62M) | (34.75M) | 27.69M |
| Income Before Tax | (43.24M) | (41.31M) | (27.03M) | (62.29M) | (15.28M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (43.24M) | (41.31M) | (27.03M) | (62.29M) | (15.28M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.03) | (0.89) | (0.56) | (1.02) | (0.19) |
| EPS (Diluted) | (1.03) | (0.89) | (0.56) | (1.02) | (0.53) |
| Weighted Avg Shares | 41.85M | 46.55M | 48.03M | 60.99M | 78.96M |
| Weighted Avg Shares (Diluted) | 41.85M | 46.55M | 48.03M | 60.99M | 79.74M |
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
Intrinsic Alpha fair value
Locked
Current Price
$10.19
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.